Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 9, keine Gesamtzahl für „increases“
Suchtreffer
Begriffe & Kennungen
Orfadin · 4.8 · Summary of the safety profile By its mode of action, nitisinone increases tyrosine levels in all nitisinone-tr
Eintrag öffnenOrfadin · 4.8 · Summary of the safety profile By its mode of action, nitisinone increases tyrosine levels in all nitisinone-tr
Eintrag öffnenOrgovyx · 4.5 · *: Upon co-administration of azithromycin and relugolix, relugolix exposure increases up to 5-fold were observ
Eintrag öffnenOsenvelt · 4.8 · Accompanying increases in parathyroid hormone have also been observed in patients receiving denosumab with sev
Eintrag öffnenPlegridy · 4.8 · Hepatic transaminase abnormalities The incidence of hepatic transaminase increases was greater in patients rec
Eintrag öffnenPravafenix · 4.8 · Liver reactions: Marked and persistent increases of serum transaminases have been reported infrequently. In cl
Eintrag öffnenPravafenix · 4.8 · Skeletal muscle: Marked and persistent increases of creatine phosphokinase (CK) have been reported infrequentl
Eintrag öffnenPrevymis · 4.5 · 39 administration of letermovir may result in clinically relevant increases in the plasma concentrations of co
Eintrag öffnenQarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) · 4.8 · 10 Safety profile with and without IL-2 The combination of Qarziba with IL-2 increases the risk of adverse dru
Eintrag öffnenRaloxifene Teva · 4.5 · Raloxifene modestly increases hormone-binding globulin concentrations, including sex steroid binding globulins
Eintrag öffnenRaloxifene Teva · 4.8 · 6 Rare cases of moderate increases in AST and/or ALT have been reported where a causal relationship to raloxif
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Diltiazem (180 to 360 mg once daily), a moderately potent CYP3A4 inhibitor, causes dose-dependent increases in
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Diltiazem (180 to 360 mg once daily), a moderately potent CYP3A4 inhibitor, causes dose-dependent increases in
Eintrag öffnenRanexa (previously Latixa) · 4.5 · Diltiazem (180 to 360 mg once daily), a moderately potent CYP3A4 inhibitor, causes dose-dependent increases in
Eintrag öffnenRapamune · 4.8 · Hepatoxicity has been reported. The risk may increase as the trough sirolimus level increases. Rare reports of
Eintrag öffnenRapamune · 4.8 · Hepatoxicity has been reported. The risk may increase as the trough sirolimus level increases. Rare reports of
Eintrag öffnenRapamune · 4.8 · Immunosuppression increases the susceptibility to the development of lymphoma and other malignancies, particul
Eintrag öffnenRapamune · 4.8 · Immunosuppression increases the susceptibility to the development of lymphoma and other malignancies, particul
Eintrag öffnenRapamune · 4.8 · The incidence of any adverse reaction(s) may increase as the trough sirolimus level increases.
Eintrag öffnenRapamune · 4.8 · The incidence of any adverse reaction(s) may increase as the trough sirolimus level increases.
Eintrag öffnen